Definium Therapeutics (DFTX) Capital Expenditures (2023 - 2026)
Definium Therapeutics (DFTX) posted quarterly Capital Expenditures of -$118000.0 for Q1 2026, down 1280.0% year-over-year from $10000.0 in Q1 2025, and down 594.12% quarter-over-quarter from -$17000.0 in Q4 2025.
Powered by 
Analysis
Definium Therapeutics (DFTX) Capital Expenditures (2023 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has reported Capital Expenditures for 4 consecutive years, with -$118000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 1280.0% year-over-year to -$118000.0; the TTM figure through Mar 2026 stood at -$158000.0 (down 664.29% YoY), while the FY2025 annual figure was -$30000.0, up 37.5% from the prior year.
- Capital Expenditures eased to -$118000.0 in Q1 2026 per DFTX's latest filing, from -$17000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $67000.0 in Q4 2024 and bottomed at -$118000.0 in Q1 2026.
- Historically, Capital Expenditures has averaged -$19000.0 across 4 years, with a median of -$17000.0 in 2023.
- Annual changes were most pronounced in 2024 — Capital Expenditures jumped 644.44% — and 2026, when it slumped 1280.0%.
- Definium Therapeutics' Capital Expenditures stood at $9000.0 in 2023, then surged by 644.44% to $67000.0 in 2024, then slumped by 125.37% to -$17000.0 in 2025, then tumbled by 594.12% to -$118000.0 in 2026.
- Business Quant data shows DFTX's Capital Expenditures at -$118000.0 in Q1 2026, -$17000.0 in Q4 2025, and -$11000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Definium Therapeutics | 4.23 Bn | 4.23 Bn | - | 133,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 133,000.00 |
| Mar 31, 2026 | -118,000.00 |
| Dec 31, 2025 | -17,000.00 |
| Sep 30, 2025 | -11,000.00 |
| Jun 30, 2025 | -12,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Dec 31, 2024 | 67,000.00 |
| Sep 30, 2024 | -25,000.00 |
| Jun 30, 2024 | -24,000.00 |
| Mar 31, 2024 | -66,000.00 |
| Dec 31, 2023 | 9,000.00 |
| Sep 30, 2023 | -25,000.00 |
| Jun 30, 2023 | -17,000.00 |
| Mar 31, 2023 | -18,000.00 |